Search results

1. The study of synergistic inhibition of tumor cell proliferation by CK2 casein kinase inhibitors and inhibitors of thymid…

Principal investigator: prof. Maria Wanda Bretner

Politechnika Warszawska, Wydział Chemiczny

Call: OPUS 7, Panel: NZ7

2. Human exosomes as natural carriers of protein kinase CK2 inhibitors and degraders in targeted anticancer therapy.

Principal investigator: dr hab. Patrycja Joanna Wińska

Politechnika Warszawska

Call: OPUS 28 (LAP), Panel: NZ5

3. New opportunities for use of PERK kinase inhibitors in eIF2alfa factor-dependant signalling pathway in antitumor therapy

Principal investigator: dr Wioletta Julia Rozpędek-Kamińska

Uniwersytet Medyczny w Łodzi, Wydział Lekarski

Call: PRELUDIUM 10, Panel: NZ3

4. Analysis of pharmacokinetic, pharmacodynamic and molecular determinants of intolerance and resistance to the Janus kinas…

Principal investigator: prof. Marta Katarzyna Karaźniewicz-Łada

Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu

Call: OPUS 27, Panel: NZ7

5. Novel aspects of the mechanisms of vascular toxicity of tyrosine kinase inhibitors: studies on their proinflammatory act…

Principal investigator: dr Tomasz Krzysztof Prajsnar

Uniwersytet Jagielloński, Wydział Biologii

Call: OPUS 26, Panel: NZ5

6. Investigating the mechanisms of CD20 downregulation triggered by tyrosine kinase inhibitors in Philadelphia chromosome-p…

Principal investigator: Krzysztof Domka

Instytut Medycyny Doświadczalnej i Klinicznej im. Mirosława Mossakowskiego PAN

Call: PRELUDIUM 22, Panel: NZ5

7. Effects of tyrosine kinase inhibitors on Syk pathway in eNOS-based platelet subpopulations and on endothelial barrier in…

Principal investigator: dr hab. Aneta Iwona Radziwon-Balicka

Uniwersytet Jagielloński, Jagiellońskie Centrum Rozwoju Leków (JCET)

Call: POLONEZ BIS 3, Panel: NZ7

8. Iron chelators as tyrosine kinase inhibitors - a new strategy for the treatment of glioblastoma multiforme

Principal investigator: dr hab. Anna Dominika Mrozek-Wilczkiewicz

UNIWERSYTET ŚLĄSKI, Wydział Nauk Ścisłych i Technicznych

Call: PRELUDIUM BIS 2, Panel: NZ5

9. Comparative evaluation of effects of tyrosine kinase inhibitors (TKIs) on endothelial function in vivo in mice

Principal investigator: Brygida Elżbieta Marczyk

Uniwersytet Jagielloński, Jagiellońskie Centrum Rozwoju Leków (JCET)

Call: PRELUDIUM 17, Panel: NZ5

10. Insights into biological activity and mechanism of action of novel styrylquinazoline derivatives as tyrosine kinase inhi…

Principal investigator: Katarzyna Anna Malarz

UNIWERSYTET ŚLĄSKI, Wydział Matematyki, Fizyki i Chemii

Call: PRELUDIUM 12, Panel: NZ7

11. Analysis of the effectiveness of anticancer activity of tyrosine kinase inhibitors combined with nanoparticles in in vit…

Principal investigator: dr Natalia Piergies

Instytut Fizyki Jądrowej im. Henryka Niewodniczańskiego PAN

Call: SONATA 11, Panel: ST4

12. Mechanism regulating vitamin D analog cooperation with cytostatics and tyrosine kinase inhibitors in non-small cell lung…

Principal investigator: dr Ewa Agnieszka Maj

Instytut Immunologii i Terapii Doświadczalnej im. Ludwika Hirszfelda Polskiej Akademii Nauk

Call: PRELUDIUM 5, Panel: NZ4

13. Targeting adenylate kinase 4 (AK4) as a new paradigm in the treatment of non-small cell lung cancer: discovery and evalu…

Principal investigator: dr Magdalena Wujak

Uniwersytet Mikołaja Kopernika, Collegium Medicum im. Ludwika Rydygiera w Bydgoszczy

Call: OPUS 26, Panel: NZ7

14. Design of new small molecular regulators (inhibitors, activators) of the catalytic activity of adenylate kinases. Molecu…

Principal investigator: dr Anna Kozakiewicz-Piekarz

Uniwersytet Mikołaja Kopernika, Wydział Chemii

Call: OPUS 13, Panel: ST4

15. Understanding the mechanism of action for small molecule kinase inhibitors in alleviating myotonic dystrophy type 1 (DM1…

Principal investigator: dr hab. Marzena Wojciechowska

Instytut Chemii Bioorganicznej PAN

Call: OPUS 7, Panel: NZ5

16. Inhibitors of ER stress dependant PERK kinase as a novel approach for Alzheimer's therapy

Principal investigator: prof. Ireneusz Jacek Majsterek

Uniwersytet Medyczny w Łodzi, Wydział Wojskowo-Lekarski

Call: HARMONIA 5, Panel: NZ1

17. The use of olaparib and ATR / CHK1 kinase inhibitors as a targeted anti-cancer therapy based on synthetic lethality

Principal investigator: dr hab. Aneta Katarzyna Rogalska

Uniwersytet Łódzki, Wydział Biologii i Ochrony Środowiska

Call: SONATA BIS 9, Panel: NZ7

18. Molecular mechanisms of interplay between RORγ/RORγT receptors and cyclin-dependent kinase inhibitor (AT7519). Analysis …

Principal investigator: Kaja Urszula Karaś

Instytut Biologii Medycznej PAN

Call: PRELUDIUM 18, Panel: NZ7

19. Use of novel small molecule inhibitors of PERK kinase dependent UPR pathway for the colorectal cancer treatment

Principal investigator: prof. Adam Janusz Dziki

Uniwersytet Medyczny w Łodzi, Wydział Lekarski

Call: OPUS 12, Panel: NZ5

20. Use of novel small molecule inhibitors of PERK kinase dependent UPR pathway for the primary open-angle glaucoma treatmen…

Principal investigator: prof. Ireneusz Jacek Majsterek

Uniwersytet Medyczny w Łodzi, Wydział Lekarski

Call: OPUS 11, Panel: NZ5

21. Studies on the influence of selected inhibitors of kinases involved in signaling pathways in tumor cells on NK cell cyto…

Principal investigator: Marta Siernicka

Warszawski Uniwersytet Medyczny, I Wydział Lekarski

Call: PRELUDIUM 7, Panel: NZ6

22. Multitarget approach to break the vicious circle of tau pathology and neuroinflammation in Alzheimer's disease: developm…

Principal investigator: dr hab. Anna Karolina Więckowska

Uniwersytet Jagielloński, Collegium Medicum

Call: SONATA BIS 9, Panel: NZ7

23. Deciphering molecular mechanism of CDK8 kinase inhibitors action in acute myeloid leukemia

Principal investigator: dr hab. Michał Marek Mikula

Centrum Onkologii - Instytut im. Marii Skłodowskiej-Curie

Call: SONATA BIS 8, Panel: NZ2

24. Synthesis of new glutamate receptors antagonists and extensive investigation of their effect on tumor cells in the prese…

Principal investigator: prof. Maria Wanda Bretner

Politechnika Warszawska, Wydział Chemiczny

Call: OPUS 9, Panel: ST5

25. New MOF compounds as degradable nanocontainers of tyrosine kinases inhibitors in novel anti-cancer therapy

Principal investigator: prof. Artur Piotr Terzyk

Uniwersytet Mikołaja Kopernika, Wydział Chemii

Call: OPUS 9, Panel: ST5

26. Search for novel IKK-β inhibitors in the context of diseases with neuroinflammatory origin – structure-based drug design…

Principal investigator: Emilia Aleksandra Sługocka

Uniwersytet Jagielloński, Collegium Medicum

Call: PRELUDIUM 22, Panel: NZ7

27. Small-molecule inhibitors of protein aggregation and ER stress as a novel strategy against neurodegeneration in the cour…

Principal investigator: prof. Ireneusz Jacek Majsterek

Uniwersytet Medyczny w Łodzi

Call: PRELUDIUM BIS 3, Panel: NZ5

28. Inhibition of p21-Activated Kinase (PAK) as a new molecular target in the treatment of chronic myeloid leukemia (CML)

Principal investigator: dr hab. Sylwia Flis

Narodowy Instytut Leków

Call: OPUS 6, Panel: NZ7

29. Targeting Energy Metabolism for Precision Cancer Therapy: Novel Inhibitors of LDH-A and PDK1 as Potential Strategies to …

Principal investigator: Marika Anna Frańczak

Gdański Uniwersytet Medyczny, Wydział Lekarski

Call: PRELUDIUM 22, Panel: NZ7

30. Kinases of emerging relevance in cancer - structural characterization.

Principal investigator: dr Grzegorz Dubin

Uniwersytet Jagielloński, Wydział Biochemii, Biofizyki i Biotechnologii

Call: SONATA BIS 2, Panel: NZ1

31. Study of casein kinase CK2 inhibition mechanisms

Principal investigator: prof. Maria Wanda Bretner

Politechnika Warszawska, Wydział Chemiczny

Call: OPUS 1, Panel: ST5

32. Selective inhibition of Janus kinases for the treatment of autoimmune hepatitis: Translational PK/PD modelling from mole…

Principal investigator: dr Artur Świerczek

Uniwersytet Jagielloński, Collegium Medicum

Call: SONATA 19, Panel: NZ7

33. New strategies in the treatment of non-small cell lung cancer based on silk nanocarriers targeting tumor vascularization

Principal investigator: dr Anna Katarzyna Florczak-Substyk

Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu

Call: SONATA 17, Panel: NZ7

34. RE-SENSE: Dual-loaded lipid nanoparticles to overcome the resistance of non-small cell lung cancer cells to personalized…

Principal investigator: Mikołaj Czajkowski

Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu

Call: PRELUDIUM 20, Panel: NZ7

35. Cell-based high-throughput screening for small-molecule compounds diminishing molecular markers of pathogenesis in myoto…

Principal investigator: dr hab. Marzena Wojciechowska

Instytut Chemii Bioorganicznej PAN

Call: OPUS 20, Panel: NZ3

36. A novel approach based on the optimized multidrug combination for glioblastoma treatment.

Principal investigator: prof. Małgorzata Kucińska

Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu

Call: SONATA 16, Panel: NZ7

37. Restoration of beta-cell function via inhibition of diabetic kinome.

Principal investigator: dr Anna Czarna

Uniwersytet Jagielloński

Call: SONATA BIS 9, Panel: NZ1

38. Protein and gene expression analysis in the course of renal cancer stem-like cells' primary resistance to sorafenib in h…

Principal investigator: Zofia Felicja Bielecka

Wojskowy Instytut Medyczny

Call: PRELUDIUM 9, Panel: NZ5

Projects search